Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
HOUSTON, TX, Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Nexalin Technology, Inc. ( Nasdaq: NXL ) ( the "Company" or "Nexalin" ) , the leader in Deep Intracranial Frequency Stimulation ( DIFS™ ) of the brain, today announced that its Gen-2 Console ( "SYNC" ) , 15 milliamp ( mA ) neurostimulation device ...
How this was made
The 30-second read
Why it matters
The approval in Israel signifies recognition of the device's safety and efficacy, opening avenues for sales and clinical adoption.
Market read
This regulatory milestone enhances NXL's market credibility and could accelerate revenue growth in the neurostimulation segment.
What to watch
Potential delays in product rollout, competition from other neurostimulation devices, and regulatory hurdles in other regions could impact long-term prospects.
Background
Nexalin Technology specializes in Deep Intracranial Frequency Stimulation (DIFS™), a novel approach for neurostimulation therapies.
Ticker impact
Primary focus of the news, as it pertains to Nexalin Technology's product approval.
Moderate upward movement in NXL stock price over the short to medium term.
Regulatory approvals often lead to increased sales opportunities and investor confidence, especially for innovative medical devices. The company's leadership in DIFS™ technology further supports this positive outlook.
Sentiment data indicates a somewhat bullish outlook, aligning with the news of regulatory approval.
Potential for a 5-10% increase in stock price within the next 1-3 months, assuming no adverse market conditions.
While regulatory approval is positive, actual market impact depends on subsequent sales performance and broader market conditions.
Market effects
Potential growth in the neurostimulation and medical device sectors due to regulatory acceptance.
Positive impact expected primarily in Israel, with potential expansion into other markets.
Moderate; success in Israel could serve as a proof of concept for other regions.
Counterpoint
Regulatory approval does not guarantee commercial success; market adoption and reimbursement policies could limit revenue growth.
Key entities
- CompanyNexalin Technology, Inc.
A leader in neurostimulation devices utilizing DIFS™ technology.
- ProductGen-2 SYNC Device
A 15 mA neurostimulation device approved for sale in Israel.
.jpeg%253Ftrim%253D0%252C0%252C0%252C0%2526width%253D1200%2526height%253D800%2526crop%253D1200%253A800&w=3840&q=75)
